Since their 2006 discovery, human induced pluripotent stem cells (iPSCs) are applied in three major areas: disease modeling, drug discovery, and regenerative therapy. The cells hold inherent properties to self-renew and with the appropriate growth and signaling factors, they can differentiate into any cell type, such as induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) that retain the genotype of individuals from whom they were derived from and exhibit the phenotypic features of disease in vitro. The use of iPSCs and iPSC-CMs enable researchers to understand disease mechanisms, screen for drug toxicity, and predict patient responses to new drugs. To promote the availability and development of iPSC technology in cardiovascular research, the Stanford Cardiovascular Institute (SCVI) Biorepository of Human Induced Pluripotent Stem Cells for Cardiovascular Diseases (BhiPSC-CVD) curates and manages a collection of human iPSC lines, as well as provides investigators with generated iPSC materials using standardized protocols. The specific aims of BhiPSC-CVD are to: 1) recruit dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy patients from diverse racial and ethnic backgrounds with a particular emphasis on minorities (e.g., African Americans, Asians, Hispanics, and Whites); 2) create and maintain iPSC lines from the patient pool or investigator-provided de-identified blood samples; 3) perform cardiotoxicity drug screening using iPSCs and their derivatives (e.g., iPSC-CMs); 4) acquire patient medical history and transcriptome information; and 5) provide NHLBI investigators with the necessary iPSC expertise, services, and resources. Overall, BhiPSC-CVD enables research towards greater understanding of individual differences in pathobiology and in response to treatment, as well as developing and optimizing novel therapeutic strategies to treat and cure cardiovascular disease.